Delivery Order SPE2DB22D2006-SPE2DB25FW4GN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $16,124.42 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This competitively awarded, firm fixed price contract carries an ultimate completion date of July 21, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections valued at $9,805.19 on May 30, 2025, with completion scheduled for June 2, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 14, 2025. The contract is classified as firm fixed price with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the company's capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $6,148.98 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price contract with no set-aside designation, classified as a competitive delivery order under the company's broader pharmaceutical supply agreements. Performance will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14,...
- The Defense Logistics Agency (DLA) awarded a $36,746.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectables. The contract, which represents a child order under a larger indefinite delivery vehicle, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $2,383.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This non-competitive delivery order, with an ultimate completion date of July 15, 2025, represents a small-value pharmaceutical transaction supporting federal medical procurement needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The U.S. Defense Department's Medical Supply Chain awarded a $3,447.09 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency awarded a delivery order valued at $3,213.27 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price, competitively awarded delivery order was executed on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle...
- The Defense Logistics Agency awarded a $6,392.26 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for Zepbound 7.5 mg/0.5 ml pen injections. This contract represents a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and was awarded through open competition without set-aside designation. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4GNDelivery Order
The Defense Logistics Agency awarded a $27,216.21 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injections, with an ultimate completion date of September 22, 2025. This non-set-aside delivery order was competitively awarded and represents a single transaction under AmerisourceBergen's existing contract vehicles supporting federal pharmaceutical procurement. The product will be delivered to the company's Conshohocken, Pennsylvania facility, where AmerisourceBergen maintains its corporate operations as one of the nation's largest pharmaceutical distributors. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. That prime vendor agreement serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply diverse pharmaceutical products and medical supplies to military healthcare programs, the Defense Health Agency, and other federal healthcare systems. The company's federal contract portfolio demonstrates its established capability to fulfill open competition requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices critical to military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.2k | 9/19/25 |